Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Loncastuximab Tesirine, Loncastuximab tesirine, Loncastuximab tesirine and rituximab (Lonca-R), Loncastuximab tesirine and rituximab
Loncastuximab Tesirine and Acalabrutinib · 1 trial · 1 indication
Recommended phase 2 dose of loncastuximab tesirine in combination with acalabrutinib
| Arm | Type | Description |
|---|---|---|
| Dose Level 1: | EXPERIMENTAL | 45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles |
| Dose Level 2 | EXPERIMENTAL | 60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles |
| Dose Level 3 | EXPERIMENTAL | 75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles |
| Dose level 4: | EXPERIMENTAL | 90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles. |
| Name | Type | Description |
|---|---|---|
| Loncastuximab Tesirine and Acalabrutinib | DRUG | Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib |
Inclusion Criteria: \- Inclusion Criteria For all patients 1. Diagnosis of CLL according to the IwCLL criteria or SLL according to the World Health Organization (WHO) criteria. This includes previous documentation of: * Biopsy-proven small lymphocytic lymphoma OR * Diagnosis of CLL accordin...
Loncastuximab Tesirine is an investigational oncology drug being studied for post-transplant lymphoproliferative disorder, B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, central nervous system lymphoma, and relapsed diffuse large B-cell lymphoma. It is in Phase 1 clinical development and is not FDA approved.
Loncastuximab Tesirine is developed by ADC Therapeutics SA, traded on the New York Stock Exchange under the ticker ADCT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various B-cell malignancies.
Loncastuximab Tesirine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA. The drug is being studied in combination with other anti-cancer agents for relapsed or refractory B-cell non-Hodgkin lymphoma.
Loncastuximab Tesirine is being evaluated in several trials, including NCT03589469 (completed Phase 2 in relapsed/refractory DLBCL), NCT04970901 (recruiting Phase 1 LOTIS-7 in B-cell NHL), NCT06788964 (recruiting Phase 2 CORAL bridging therapy), and NCT07573436 (not yet recruiting Phase 1 PLUTO in post-transplant lymphoproliferative disorder).
Loncastuximab Tesirine is also known as Loncastuximab Tesirine and Acalabrutinib, Loncastuximab tesirine and rituximab (Lonca-R), and Loncastuximab tesirine and rituximab. These names refer to the drug in combination with other agents, while Loncastuximab Tesirine alone is the single-agent form.
Loncastuximab Tesirine is a small molecule oncology drug. The specific molecular target is not disclosed in the available information, but it is being studied in B-cell malignancies including diffuse large B-cell lymphoma and post-transplant lymphoproliferative disorder.